Financial reports
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
10 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
11 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
1 Mar 18
Current reports
8-K
Entry into a Material Definitive Agreement
22 May 20
8-K
Assertio Therapeutics Announces First-Quarter 2020 Results
11 May 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Apr 20
8-K
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting
21 Apr 20
8-K
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase
8 Apr 20
8-K
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
17 Mar 20
8-K
Assertio Therapeutics Announces Offer to Purchase
11 Mar 20
8-K
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
9 Mar 20
8-K
Unaudited Pro Forma Financial Statements
20 Feb 20
8-K
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
13 Feb 20
Registration and prospectus
15-12B
Securities registration termination
18 Jun 20
25-NSE
Exchange delisting
19 May 20
425
Business combination disclosure
11 May 20
425
Business combination disclosure
21 Apr 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Apr 20
SC TO-I/A
Issuer tender offer statement (amended)
25 Mar 20
425
Business combination disclosure
17 Mar 20
SC TO-I
Issuer tender offer statement
11 Mar 20
S-8
Registration of securities for employees
10 May 19
S-8
Registration of securities for employees
9 Nov 18
Proxies
DEFA14A
Additional proxy soliciting materials
18 May 20
DEF 14A
Definitive proxy
20 Apr 20
DEF 14A
Definitive proxy
8 Apr 19
PX14A6G
Letter to shareholders
10 Apr 18
DEF 14A
Definitive proxy
27 Mar 18
PRE 14A
Preliminary proxy
16 Mar 18
DEF 14A
Definitive proxy
14 Jul 17
PRRN14A
Revised preliminary proxy statement filed by non-management
5 Oct 16
PRER14A
Preliminary revised proxy
4 Oct 16
DEFA14A
Additional proxy soliciting materials
26 Sep 16
Other
UPLOAD
Letter from SEC
11 Feb 19
CORRESP
Correspondence with SEC
16 Jan 19
UPLOAD
Letter from SEC
19 Dec 18
CORRESP
Correspondence with SEC
19 Dec 18
EFFECT
Notice of effectiveness
21 Aug 18
EFFECT
Notice of effectiveness
10 Apr 18
CORRESP
Correspondence with SEC
6 Apr 18
CT ORDER
Confidential treatment order
19 Mar 18
CT ORDER
Confidential treatment order
30 Nov 17
UPLOAD
Letter from SEC
1 Feb 17
Ownership
SC 13G/A
Allianz Global Investors U.S. Holdings LLC
12 Feb 21
4
KAREN A DAWES
11 May 20
4/A
Stan Bukofzer
3 Apr 20
4
Stan Bukofzer
3 Apr 20
4
James Galeota JR
31 Mar 20
SC 13D
Zyla Life Sciences
26 Mar 20
4
Heather L Mason
19 Feb 20
SC 13G/A
Assertio Therapeutics, Inc
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Assertio Therapeutics, Inc
13 Feb 20